Abstract
Central nervous system (CNS) metastases from epithelial ovarian cancer (EOC) are rare, occurring in approximately 1–2% of patients. This retrospective study of 94 patients from two major academic institutions in Korea and Taiwan investigated clinico-pathological prognostic factors and compared treatment outcomes. Key findings indicate that serous histology, absence of progressive disease at CNS diagnosis, and CNS involvement occurring after the first disease relapse are associated with significantly improved survival. Most importantly, Gamma Knife Radiosurgery (GKS)-based combination treatments provided a substantial survival benefit, particularly for patients whose CNS metastases were not part of their initial disease recurrence.
Introduction
Epithelial ovarian cancer (EOC) typically spreads within the peritoneal cavity. Metastasis to the central nervous system (brain or spinal cord) is an infrequent but devastating event, often associated with a poor prognosis. Historically, Whole Brain Radiation Therapy (WBRT) was the mainstay of treatment; however, its efficacy is limited by poor local control and significant neurocognitive side effects. Stereotactic radiosurgery, specifically Gamma Knife Radiosurgery (GKS), has emerged as a precise alternative that delivers high-dose radiation with sub-millimeter accuracy. However, its role in combination with other modalities for EOC patients has lacked multi-institutional validation until now.
Methods and Patient Assessment
The study retrospectively reviewed 6,300 EOC cases treated between 2000 and 2020 at Samsung Medical Center (Korea) and National Taiwan University Hospital (Taiwan). Ninety-four patients with CNS metastases were identified, representing an incidence rate of 1.49%. Patients were categorized into four treatment groups: RT only (conventional radiation), RT-based combination, GKS only, and GKS-based combination (GKS plus surgery, chemotherapy, or conventional RT).
Clinical assessment for GKS-based strategies followed specific criteria, including life expectancy, performance status, and tumor burden, as outlined in the clinical practice workflow.
Key Results
The median survival after CNS metastasis diagnosis across the entire cohort was 11.9 months. Several factors were identified as significant predictors of survival:
- Histology: Patients with serous histological types had a significantly lower risk of death (Hazard Ratio [HR]: 0.49) compared to non-serous types.
- Relapse Timing: Patients whose CNS involvement occurred after their first disease relapse had better survival outcomes, suggesting that early CNS spread may indicate a more aggressive phenotype.
- Treatment Efficacy: GKS-based combination therapy significantly reduced the risk of death (HR: 0.59, p < 0.001) and achieved the highest therapeutic response rate (80%).
In a notable subgroup analysis, patients whose CNS involvement was not the first recurrence and who received GKS-based combination therapy achieved a median survival of 32.9 months, compared to only 3.1 months for those receiving conventional RT alone.
Discussion and Conclusion
The timing of CNS metastasis appears to be a critical indicator of tumor biology. While "early" CNS spread (at first relapse) reflects a treatment-resistant phenotype, patients with later CNS involvement benefit significantly from the aggressive local control provided by GKS combined with systemic or surgical interventions.
GKS-based treatments resulted in the longest CNS recurrence-free intervals (9.7 months), suggesting that superior local control in the brain directly translates to extended overall survival. These findings support the use of GKS-based combination strategies as a preferred approach for eligible EOC patients with CNS metastases to maximize both survival and quality of life.
Summary updated